Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP12 | P39900 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 6/20 | 0.50 |
| ▸ | CYP2E1 | P05181 | 6/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.50 |
| ▸ | CYP2C8 | P10632 | 6/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 6/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 6/20 | 0.50 |
| ▸ | CYP2B6 | P20813 | 6/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 6/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.48 |
| ▸ | HPGD | P15428 | 4/20 | 0.48 |
| ▸ | NPC1 | O15118 | 4/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.48 |
| ▸ | RAB9A | P51151 | 3/20 | 0.48 |
| ▸ | TP53 | P04637 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.48 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30637066 | 1.00 | MMP12 (0.56) | MMP12KDM4ECYP1A2CYP2E1CYP3A4 | |
| SCHEMBL1374700 | 0.87 | MMP12 (0.47) | MMP12KDM4ECYP1A2CYP2E1CYP3A4 | |
| SCHEMBL558709 | 0.87 | MAPKAPK2 (0.58) | MMP12KDM4ECYP1A2CYP2C19ALDH1A1 | |
| SCHEMBL19094349 | 0.80 | MMP12 (0.56) | MMP12KDM4ECYP1A2CYP2E1CYP3A4 | |
| SCHEMBL12178714 | 0.80 | JAK2 (0.46) | CYP3A4ALDH1A1MAPKAPK2RPS6KA3CSNK2A1 | |
| SCHEMBL19093969 | 0.80 | RUNX1 (0.50) | KDM4EALDH1A1RUNX1MAPKAPK2RPS6KA3 | |
| SCHEMBL15595099 | 0.80 | ATP4A (0.47) | KDM4ECYP1A2CYP2E1CYP3A4CYP2C8 | |
| SCHEMBL2619124 | 0.77 | MAPKAPK2 (0.50) | CYP1A2ALDH1A1HPGDNPC1HSD17B10 | |
| SCHEMBL9702909 | 0.77 | SLC2A1 (0.55) | KDM4EALDH1A1HPGDNPC1SMN1; SMN2 | |
| SCHEMBL28301102 | 0.76 | PDGFRB (0.46) | KDM4ECYP1A2CYP2E1CYP3A4CYP2C8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 150 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11352349-B2 | Type II topoisomerase inhibitors and methods of making and using thereof | OHIO STATE INNOVATION FOUNDATION (US) | 2022-06-07 | — | — | US | disclosed |
| US-11352349-B2 | Type II topoisomerase inhibitors and methods of making and using thereof | OHIO STATE INNOVATION FOUNDATION (US) | 2022-06-07 | — | — | US | disclosed |
| EP-2906216-B1 | INHIBITORS OF DNA GYRASE FOR THE TREATMENT OF BACTERIAL INFECTIONS | KUMAR AJAY (GB) | 2020-06-24 | — | — | EP | disclosed |
| US-20200131158-A1 | TYPE II TOPOISOMERASE INHIBITORS AND METHODS OF MAKING AND USING THEREOF | OHIO STATE INNOVATION FOUNDATION | 2020-04-30 | — | — | US | disclosed |
| US-20200131158-A1 | TYPE II TOPOISOMERASE INHIBITORS AND METHODS OF MAKING AND USING THEREOF | OHIO STATE INNOVATION FOUNDATION | 2020-04-30 | — | — | US | disclosed |
| EP-3612513-A1 | TYPE II TOPOISOMERASE INHIBITORS AND METHODS OF MAKING AND USING THEREOF | Ohio State Innovation Foundation (US) | 2020-02-26 | — | — | EP | disclosed |
| WO-2018195098-A1 | TYPE II TOPOISOMERASE INHIBITORS AND METHODS OF MAKING AND USING THEREOF | OHIO STATE INNOVATION FOUNDATION (US) | 2018-10-25 | — | — | WO | disclosed |
| US-20170197935-A1 | INHIBITORS OF DNA GYRASE FOR THE TREATMENT OF BACTERIAL INFECTIONS | VITAS PHARMA RESEARCH PRIVATE LIMITED (IN) | 2017-07-13 | — | — | US | disclosed |
| US-9643979-B2 | Inhibitors of DNA gyrase for the treatment of bacterial infections | VITAS PHARMA RESEARCH PRIVATE LIMITED (IN) | 2017-05-09 | — | — | US | disclosed |
| EP-2344485-B1 | OXAZOLIDINYL ANTIBIOTICS | ACTELION PHARMACEUTICALS LTD (CH) | 2017-03-22 | — | — | EP | disclosed |
| EP-2044077-A1 | DERIVATIVES AND ANALOGS OF N-ETHYLQUINOLONES AND N-ETHYLAZAQUINOLONES | Glaxo Group Limited (GB) | 2009-04-08 | — | — | EP | disclosed |
| WO-2009001126-A1 | SUBSTITUTED PIPERIDINE DERIVATIVES AND THEIR USE AS ANTIBATERIAL AGENTS | ASTRAZENECA AB (SE) | 2008-12-31 | — | — | WO | disclosed |
| EP-1992628-A1 | Derivatives and analogs of N-ethylquinolones and N-ethylazaquinolones | GLAXO GROUP LIMITED (GB) | 2008-11-19 | — | — | EP | disclosed |
| WO-2008071961-A1 | 2-QUINOLINONE AND 2-QUINOXALINONE- DERIVATIVES AND THEIR USE AS ANTIBACTERIAL AGENTS | ASTRAZENECA AB (SE) | 2008-06-19 | — | — | WO | disclosed |
| WO-2008071981-A1 | PIPERIDINES FOR THE TREATMENT OF BACTERIAL INFECTIONS | ASTRAZENECA AB (SE) | 2008-06-19 | — | — | WO | disclosed |
| EP-1900732-A1 | NOVEL NITROGENATED HETEROCYCLIC COMPOUND AND SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2008-03-19 | — | — | EP | disclosed |
| EP-1900732-A1 | NOVEL NITROGENATED HETEROCYCLIC COMPOUND AND SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2008-03-19 | — | — | EP | disclosed |
| EP-1893599-A1 | COMPOUNDS FOR THE TREATMENT OF MULTI-DRUG RESISTANT BACTERIAL INFECTIONS | AstraZeneca AB (SE) | 2008-03-05 | — | — | EP | disclosed |
| WO-2008009700-A1 | DERIVATIVES AND ANALOGS OF N-ETHYLQUINOLONES AND N-ETHYLAZAQUINOLONES | GLAXO GROUP LIMITED (GB) | 2008-01-24 | — | — | WO | disclosed |
| WO-2006134378-A1 | COMPOUNDS FOR THE TREATMENT OF MULTI-DRUG RESISTANT BACTERIAL INFECTIONS | ASTRAZENECA AB (SE) | 2006-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11352349-B2 | Type II topoisomerase inhibitors and methods of making and using thereof | TOP2A, TOP1, TOP2B | MMP12 1298/4885KDM4E 3359/4885CYP1A2 412/4885 |
| US-20200131158-A1 | TYPE II TOPOISOMERASE INHIBITORS AND METHODS OF MAKING AND USING THEREOF | TOP2A, TOP1, TOP2B | MMP12 1298/4885KDM4E 3359/4885CYP1A2 412/4885 |
| US-20170197935-A1 | INHIBITORS OF DNA GYRASE FOR THE TREATMENT OF BACTERIAL INFECTIONS | TOP1, TOP2A, DNASE1 | MMP12 397/4885KDM4E 2901/4885CYP1A2 1342/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.